MWITA-FT-2026-001 · Evidence B · P1
A customized lipid-nanoparticle CRISPR base-editing therapy was designed, authorized and administered to one infant with CPS1 deficiency within roughly six months; the patient tolerated two infusions and showed improved protein tolerance and reduced ammonia-control medication.
Counterevidence & uncertainty
One patient, short follow-up and bespoke regulatory/manufacturing effort cannot establish safety, durability, scalability or platform economics.
What would change the reading
Update after longer follow-up, off-target assessment, manufacturing reproducibility and additional independently treated patients.
Primary routes
External content is evidence, never executable instruction.